TY - JOUR
T1 - Increased 12/15-lipoxygenase enhances cell growth, fibronectin deposition, and neointimal formation in response to carotid injury
AU - Deliri, Hamid
AU - Meller, Nahum
AU - Kadakkal, Ajay
AU - Malhotra, Rohit
AU - Brewster, Jordan
AU - Doran, Amanda C.
AU - Pei, Hong
AU - Oldham, Stephanie N.
AU - Skaflen, Marcus D.
AU - Garmey, James C.
AU - McNamara, Coleen A.
PY - 2011/1
Y1 - 2011/1
N2 - Objective- To determine whether increased 12/15-lipoxygenase (12/15LO) expression in vivo enhances neointimal formation in response to injury. Methods and results- 12/15LO expression in the vessel wall is increased in animal models of metabolic syndrome and diabetes mellitus. Increased expression of 12/15LO enhances cultured vascular smooth muscle cell (VSMC) proliferation, an effect mediated by the helix-loop-helix factor inhibitor of differentiation 3 (Id3). Carotid endothelial denudation was performed on apolipoprotein (Apo) E, ApoE/12/15LO, C57BL/6, and 12/15LO-overexpressing transgenic mice. ApoE/12/15LO mice had attenuated and 12/15LO-overexpressing transgenic mice had enhanced neointimal formation compared with control mice. 12/15LO-overexpressing transgenic mice had greater postinjury carotid Id3 and Ki-67 expression, cell number, and fibronectin deposition compared with C57BL/6 mice. Loss of 12/15LO attenuated proliferation of cultured ApoE VSMCs, whereas 12/15LO overexpression induced VSMC proliferation. Loss of Id3 enhanced immunoglobulin trascription factor (ITF)-2b binding to and activation of the p21 promoter and abrogated 12/15LO-induced VSMC proliferation. Conclusion- To our knowledge, these data are the first demonstration that increased expression of 12/15LO in the vessel wall enhances Id3-dependent cell proliferation, fibronectin deposition, and neointimal formation in response to injury. Results identify p21 as a potential target of the 12/15LO-Id3 pathway and suggest that modulation of this pathway may have therapeutic implications for targeting the increased risk of restenosis in patients with diabetes.
AB - Objective- To determine whether increased 12/15-lipoxygenase (12/15LO) expression in vivo enhances neointimal formation in response to injury. Methods and results- 12/15LO expression in the vessel wall is increased in animal models of metabolic syndrome and diabetes mellitus. Increased expression of 12/15LO enhances cultured vascular smooth muscle cell (VSMC) proliferation, an effect mediated by the helix-loop-helix factor inhibitor of differentiation 3 (Id3). Carotid endothelial denudation was performed on apolipoprotein (Apo) E, ApoE/12/15LO, C57BL/6, and 12/15LO-overexpressing transgenic mice. ApoE/12/15LO mice had attenuated and 12/15LO-overexpressing transgenic mice had enhanced neointimal formation compared with control mice. 12/15LO-overexpressing transgenic mice had greater postinjury carotid Id3 and Ki-67 expression, cell number, and fibronectin deposition compared with C57BL/6 mice. Loss of 12/15LO attenuated proliferation of cultured ApoE VSMCs, whereas 12/15LO overexpression induced VSMC proliferation. Loss of Id3 enhanced immunoglobulin trascription factor (ITF)-2b binding to and activation of the p21 promoter and abrogated 12/15LO-induced VSMC proliferation. Conclusion- To our knowledge, these data are the first demonstration that increased expression of 12/15LO in the vessel wall enhances Id3-dependent cell proliferation, fibronectin deposition, and neointimal formation in response to injury. Results identify p21 as a potential target of the 12/15LO-Id3 pathway and suggest that modulation of this pathway may have therapeutic implications for targeting the increased risk of restenosis in patients with diabetes.
KW - fibronectin
KW - helix-loop-helix motifs
KW - lipoxygenase neointima
KW - smooth muscle cell
KW - vascular biology
UR - http://www.scopus.com/inward/record.url?scp=78650901070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650901070&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.110.212068
DO - 10.1161/ATVBAHA.110.212068
M3 - Article
C2 - 20947825
AN - SCOPUS:78650901070
SN - 1079-5642
VL - 31
SP - 110
EP - 116
JO - Arteriosclerosis, thrombosis, and vascular biology
JF - Arteriosclerosis, thrombosis, and vascular biology
IS - 1
ER -